Please ensure Javascript is enabled for purposes of website accessibility

Here's Why AVEO Pharmaceuticals Dropped as Much as 16.3% Today

By Maxx Chatsko - Updated Oct 17, 2017 at 3:56PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares have seen increased volatility despite the company gaining its first-ever marketing approval recently.

What happened

Shares of surprise biopharma AVEO Pharmaceuticals (AVEO 2.43%) dropped over 16% today on nearly twice the daily average trading volume without any major news story breaking. What's going on? Unfortunately, this is simply what stocks do. Sometimes they go up (a lot), sometimes they go down (a lot).

Of course, daily market movements caused by day traders reading technical charts shouldn't influence your opinion of the company. If you liked AVEO Pharmaceuticals yesterday or last week, then today's move shouldn't do anything to change your thinking. As of 3:31 p.m. EDT, the stock had settled to a 12.9% loss.

Two polished metal spheres balancing on a seesaw, with one side touching the ground and the other in the air.

Image source: Getty Images.

So what

AVEO Pharmaceuticals has been one of the best -- and most surprising -- stocks of 2017. No one gave it a chance at gaining marketing approval for Fotivda. Given the drug candidate's poor track record of failed clinical trials, that was a reasonable bet. But when European regulators took a favorable view of the therapeutic earlier this summer, the stock jumped from the depths of obscurity at $0.75 per share to become the "must own momo" stock. It recently hit new highs near $4 per share, but has since pulled back to around $3 per share.

The stock's recent past also has an unhappy side effect for shareholders: AVEO Pharmaceuticals stock will continue to be heavily traded and shorted as Mr. Market sorts out his emotions. Today's move is a reminder that volatility will remain for the foreseeable future.

Now what

While existing shareholders should mostly ignore the noise of daily volatility, it's still very important to remain updated on the company's progress. How Fotivda will fare once available to patients in Europe is still a relative unknown and success is hardly guaranteed. Also, the upcoming data readout expected in the first quarter of 2018 from a large U.S. phase 3 trial is a binary catalyst with huge implications for the future of AVEO Pharmaceuticals. With additional early and mid-stage pipeline studies thrown in, there are quite a few moving pieces to keep track of.

Then again, often times staying informed is easier for individual investors than controlling emotions, but it's definitely worth it in the end.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AVEO Pharmaceuticals, Inc. Stock Quote
AVEO Pharmaceuticals, Inc.
$7.17 (2.43%) $0.17

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.